EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.